Cardiovascular Manifestations of Diabetes Mellitus: A Narrative Review of Literatures
International Journal of Clinical and Experimental Medical Sciences
Volume 2, Issue 5, September 2016, Pages: 67-77
Received: May 10, 2016; Accepted: Jun. 3, 2016; Published: Aug. 4, 2016
Views 3844      Downloads 137
Authors
Seyed Mohammad Yousof Mostafavi-Pour-Manshadi, Department of Medicine, Division of Experimental Medicine, Research Institute of McGill University Health Center, McGill University, Montreal, Quebec, Canada
Nafiseh Naderi, Department of Medicine, Division of Experimental Medicine, Research Institute of McGill University Health Center, McGill University, Montreal, Quebec, Canada
Abolfazl Dehghan, Department of Medicine, Ali Ben Abitalib Medical College, Islamic Azad University, Yazd, Iran
Sanaz Azizi, Department of Medicine, Ali Ben Abitalib Medical College, Islamic Azad University, Yazd, Iran
Article Tools
Follow on us
Abstract
There are many studies documenting that diabetes mellitus is associated with cardiovascular diseases. Diabetes mellitus has a significant role and is an important risk factor in cardiovascular manifestations in patients with diabetes mellitus. Cardiovascular diseases are one of the main causes of morbidity and mortality in diabetic patients. Diabetes mellitus can affect performance, construction, and the anatomy of the heart and vessels. As a result, it can lead to cardiovascular complications, such as left ventricular systolic and diastolic dysfunction, left ventricular hypertrophy, coronary heart disease, peripheral artery disease, myocardial infarction, congestive heart failure, and cardiomyopathy. Different mechanisms of diabetes mellitus play an important role in the manifestations of cardiovascular diseases in diabetic patients. Understanding of these mechanisms can help physicians recognize, prevent, and treat the associated cardiovascular complications of diabetes mellitus. A detailed investigation of cardiovascular complications and diseases might be significant in the prognosis of diabetic patients and can be useful in managing and treating such patients.
Keywords
Cardiovascular Manifestations, Diabetes Mellitus, Heart Failure, Cardiomyopathy, Cardiovascular Diseases, Cardiovascular Complications
To cite this article
Seyed Mohammad Yousof Mostafavi-Pour-Manshadi, Nafiseh Naderi, Abolfazl Dehghan, Sanaz Azizi, Cardiovascular Manifestations of Diabetes Mellitus: A Narrative Review of Literatures, International Journal of Clinical and Experimental Medical Sciences. Vol. 2, No. 5, 2016, pp. 67-77. doi: 10.11648/j.ijcems.20160205.11
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Freire CM, Moura AL, Barbosa Mde M, Machado LJ, Nogueira AI, Ribeiro-Oliveira Jr A. Left ventricle diastolic dysfunction in diabetes: an update. Arq Bras Endocrinol Metabol. 2007;51:168-175.
[2]
Li YW, Aronow WS. Diabetes Mellitus and Cardiovascular Disease. Journal of Clinical and Experimental Cardiology. 2011;2:114.
[3]
Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146.
[4]
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
[5]
Laakso M. Heart in diabetes: a microvascular disease. Diabetes Care. 2011;34:S145-9.
[6]
Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is... or is it? Lancet. 1997;350:SI4-9.
[7]
Stephens JW, Humphries SE, Cooper JA, Hurel SJ. What are the clinical manifestations of cardiovascular disease in diabetes? Ten year analysis from a clinic based population. British Journal of Diabetes & Vascular Disease. 2004;4:190.
[8]
Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004;292:2495-2499.
[9]
Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119:1728-1735.
[10]
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
[11]
Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004;164:2147-2155.
[12]
Gao Y, Lu B, Sun ML, et al Comparison of atherosclerotic plaque by computed tomography angiography in patients with and without diabetes mellitus and with known or suspected coronary artery disease. Am J Cardiol. 2011;108:809-813.
[13]
Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res. 2006;98:596-605.
[14]
Picano E. Diabetic cardiomyopathy. The importance of being earliest. J Am Coll Cardiol. 2003;42:454 –457.
[15]
Avogaro A, Vigili dKS, Negut C, Tiengo A, Scognamiglio R. Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol 2004;93:13A–16A.
[16]
Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem. 2004;261:187–191.
[17]
Bellmann B, Tschöpe C. [Heart failure. Cardiovascular autonomic neuropathy in patients with diabetes mellitus]. Herz. 2014;39: 306-311.
[18]
Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11:31-39.
[19]
Guha A1, Harmancey R, Taegtmeyer H. Nonischemic heart failure in diabetes mellitus. Curr Opin Cardiol. 2008;23:241-248.
[20]
Solang L, Malmberg K, Ryden L.Diabetes mellitus and congestive heart failure. Eur Heart J. 1999;20:789–795.
[21]
Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). Am J Cardiol. 1992;69:1458–1466
[22]
Akasaka T, Yoshida K, Hozumi T, et al. Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus. J Am Coll Cardiol. 1997;30:935–941.
[23]
Margonato A, Gerundini P, Vicedomini G, Gilardi MC, Pozza G, Fazio F. Abnormal cardiovascular response to exercise in young asymptomatic diabetic patients with retinopathy. Am Heart J. 1986;112:554-560.
[24]
Hunt SA, Baker DW, Chin MH, et al: ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Circulation. 2001;104:2996–3007.
[25]
Gutierrez C, Blanchard DG. Diastolic heart failure: challenges of diagnosis and treatment. Am Fam Phys. 2004;69:2609–2616.
[26]
Marwick TH. Diabetic heart disease. Heart. 2006;92:296–300.
[27]
Schainberg A, Ribeiro-Oliveira Jr A, Ribeiro JM. Is there a link between glucose levels and heart failure? An update. Arq Bras Endocrinol Metabol. 2010;54:488-497.
[28]
Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77:1017-1020.
[29]
Piccini JP, Klein L, Gheorghiade M, Bonow RO. New insights into diastolic heart failure: role of diabetes mellitus. Am J Med. 2004;116:64S-75S.
[30]
Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care. 2003;26:2791-2795.
[31]
Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614-1619.
[32]
Gustafsson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43:771-777.
[33]
Zarich SW, Arbuckle BE, Cohen LR, Roberts M, Nesto RW. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol. 1998;12:114-120.
[34]
Raev DC. Which left ventricular dysfunction is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type 1 diabetic patients. Diabetes Care. 1994;17: 633-639.
[35]
Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community. JAMA. 2003;289:194–202.
[36]
Cooper GJ, Phillips AR, Choong SY, et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes. 2004;53:2501-2508.
[37]
Kitzman DW, Gardin JM, Gottdiener JS, et al; Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001;15;87:413-419.
[38]
Aronow WS, Ahn C, Kronzon I. Comparisons of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999;84:611-612.
[39]
Aronow WS, Ahn C. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest. 1999;115:867-868.
[40]
Halon DA, Merdler A, Flugelman MY, et al. Late onset heart failure as a mechanism for adverse long-term outcome in diabetic patients undergoing revascularization (a 13-year report from the Lady Davis Carmel Medical Center registry). Am J Cardiol. 2000;85:1420-1426.
[41]
Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE trial). Am J Cardiol. 2008;101:634-638.
[42]
Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation. 2003;107:448-454.
[43]
Oliveira AP, Calderon IM, Costa RA, Roscani MG, Magalhães CG, Borges VT. Assessment of structural cardiac abnormalities and diastolic function in women with gestational diabetes mellitus. Diab Vasc Dis Res. 2015;12:175-180.
[44]
Greenberg BH, Abraham WT, Albert NM, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2007;154:277.
[45]
Van Heerebeek L, Paulus WJ. Invasive evaluation of diastolic left ventricular dysfunction. In: Smiseth O, Tendera M, eds. Diastolic heart failure. London: Springer; 2007. p. 137-48.
[46]
Ingelsson E1, Sundström J, Arnlöv J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;20;294:334-341.
[47]
Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121:951-957.
[48]
He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996-1002.
[49]
Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000;101:2271-2276.
[50]
Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J. 2000;21:1368-1375.
[51]
Nakai H1, Takeuchi M, Nishikage T, Lang RM, Otsuji Y. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr. 2009;10:926-932.
[52]
Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006;48:1548–1551.
[53]
Henein MY, Gibson DG. Long axis function in disease. Heart. 1999;81:229–231.
[54]
Ha JW, Lee HC, Kang ES, et al. Abnormal left ventricular longitudinal functional reserve in patients with diabetes mellitus: implication for detecting subclinical myocardial dysfunction using exercise tissue Doppler echocardiography. Heart. 2007;93:1571–1576.
[55]
Tenenbaum A, Fisman EZ, Schwammenthal E, et al. Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus. Cardiovasc Diabetol. 2003;2:14.
[56]
Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85-89.
[57]
Neubauer B, Christensen NJ. Norepinephrine, epinephrine, and dopamine contents of the cardiovascular system in long-term diabetes. Diabetes. 1976;25:6-10.
[58]
Chiariello M, Indolfi C. Silent myocardial ischemia in patients with diabetes mellitus. Circulation. 1996;93:2089-2091.
[59]
Dagres N, Saller B, Haude M, et al. Insulin sensitivity and coronary vasoreactivity: insulin sensitivity relates to adenosine-stimulated coronary flow response in human subjects. Clin Endocrinol (Oxf). 2004;61:724 –731.
[60]
Dietz U, Tries HP, Merkle W, Jaursch-Hancke C, Lambertz H. Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil. Cardiovasc Diabetol. 2003;2:8.
[61]
Pop-Busui R, Kirkwood I, Schmid H, et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol. 2004;44:2368 –2374.
[62]
Dortimer AC, Shenoy PN, Shiroff RA, et al. Diffuse coronary artery disease in diabetic patients: fact or fiction? Circulation. 1978;57:133-136.
[63]
Bartnik M1, Rydén L, Ferrari R, et al; Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25:1880-1890.
[64]
Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000;102:2180-2184.
[65]
Thourani VH, Weintraub WS, Stein B, et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg. 1999;67:1045-1052.
[66]
Elezi S1, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32:1866-1873.
[67]
BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49:1600-1606.
[68]
Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in the Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Brit Med J. 2001;322:15–18.
[69]
DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26:688–696.
[70]
Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes. Eur Heart J. 2002;23:1190–1201.
[71]
Pyörälä K, Lehto S, De Bacquer D, et al; EUROASPIRE I Group; EUROASPIRE II Group. Risk factor management in diabetic and non-diabetic coronary heart disease patients. Findings from heart disease patients from EUROASPIRE I and II surveys. Diabetologia. 2004;47;1257–1265.
[72]
Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B–25B.
[73]
Rohrer L1, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol. 2004 ;15:269-278.
[74]
American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26:3333-3341.
[75]
Giquel J, Nieto M, Matadial C, Palermo C. Cardiovascular Manifestations of Hyperglycemia: A Review Article. J Gen Practice. 2014;2:191.
[76]
Asghar O, Al-Sunni A, Khavandi K, et al. Diabetic cardiomyopathy. Clin Sci (Lond). 2009;116:741–760.
[77]
Margolis JR, Kannel WS, Feinleib M, Dawber TR, McNamara PM. Clinical features of unrecognized myocardial infarction--silent and symptomatic. Eighteen year follow-up: the Framingham study. Am J Cardiol. 1973;32:1-7.
[78]
Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med. 1984;311:1144-1147.
[79]
Bell DSH. Stroke in the diabetic patient. Diabetes Care. 1994;17:213–219.
[80]
Folsom AR, Eckfeldt JH, Weitzman S, et al. Atherosclerosis Risk in Communities Study Investigators. Relation of carotid artery wall thickness in diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Stroke. 1994;25:66 –73.
[81]
Kuller LH, National Diabetes Data Group. Stroke and diabetes. In: Diabetes in America. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases;1995:449–456.
[82]
Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328:1676-1685.
[83]
Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 1995;26:869-879.
[84]
Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002;106:2085-2090.
[85]
Weitzman S, Wagner GS, Heiss G, Haney TL, Slome C. Myocardial infarction site and mortality in diabetes. Diabetes Care. 1982;5:31-35.
[86]
DeLuca AJ1, Kaplan S, Aronow WS, et al. Comparison of prevalence of unrecognized myocardial infarction and of silent myocardial ischemia detected by a treadmill exercise sestamibi stress test in patients with versus without diabetes mellitus. Am J Cardiol. 2006;98:1045-1046.
[87]
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
[88]
Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387-397.
[89]
Aronow W, Ahn C. Elderly diabetics with peripheral arterial disease and no coronary artery disease have a higher incidence of new coronary events than elderly non diabetics with peripheral arterial disease and prior myocardial infarction treated with statins and with no lipid-lowering drug. J Gerontol Med Sci. 2003;58:573-575.
[90]
Miettinen H, Lehto S, Salomaa V, et al. The FINMONICA Myocardial Infarction Register Study Group. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care. 1998;21:69-75.
[91]
Lundberg V, Stegmayr B, Asplund K, Eliasson M, Huhtasaari F. Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Intern Med. 1997;241:485-492.
[92]
Kautzky-Willer A, Handisurya A. Metabolic diseases and associated complications: sex and gender matter! Eur J Clin Invest. 2009;39:631-648.
[93]
Quinones MJ, Hernandez-Pampaloni M, Schelbert H, Isabel Bulnes-Enriquez, Xochi jimenez, et al. Coronary vasomotor abnormalities in insulinresistant individuals. Ann Intern Med. 2004;140:700-708.
[94]
Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol. 2002;22:1370–1380.
[95]
Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab. 2005;90:5896-5903.
[96]
Pop-Busui R. What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes. J Cardiovasc Transl Res. 2012;5:463-478.
[97]
Balcıoğlu AS, Müderrisoğlu H. Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes. 2015; 6:80-91.
[98]
Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956-962.
[99]
Vinik AI, Erbas T. Diabetic autonomic neuropathy. Handb Clin Neurol. 2013;117:279-294.
[100]
Metelka R. Heart rate variability - current diagnosis of the cardiac autonomic neuropathy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158:327-338.
[101]
Spallone V, Bernardi L, Ricordi L, et al. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes. 1993;42:1745–1752.
[102]
Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347:797–805.
[103]
Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387–397.
[104]
Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care. 2010;33:434-441.
[105]
Debono M, Cachia E. The impact of cardiovascular autonomic neuropathy in diabetes: is it associated with left ventricular dysfunction? Auton Neurosci. 2007;132:1-7.
[106]
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–1579.
[107]
Vinik AI, Freeman R, Erbas T. Diabetic autonomic neuropathy. Semin Neurol. 2003;23:365–372.
[108]
1Burgos LG, Ebert TJ, Asiddao C, et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology. 1989;70:591–597.
[109]
Wackers FJ, Young LH, Inzucchi SE, et al; Detection of Ischemia in Asymptomatic Diabetics (DIAD) Investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care. 2004;27:1954–1961.
[110]
Sivieri R, Veglio M, Chinaglia A, Scaglione P, Cavallo-Perin P. Prevalence of QT prolongation in a type 1 diabetic population and its association with autonomic neuropathy. The Neuropathy Study Group of the Italian Society for the Study of Diabetes. Diabet Med. 1993;10:920-924.
[111]
Navarro X, Kennedy WR, Sutherland DE. Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia. 1991;34:S108-S112.
[112]
Ko SH, Song KH, Park SA, et al. Cardiovascular autonomic dysfunction predicts acute ischaemic stroke in patients with Type 2 diabetes mellitus:a 7-year follow-up study. Diabet Med. 2008;25:1171-1177.
[113]
Balcıoğlu AS, Müderrisoğlu H. Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes. 2015;15;6:80-91.
[114]
Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication:a risk profile from the Framingham Heart Study. Circulation. 1997;96:44–49.
[115]
Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary
[116]
Dolan NC, Liu K, Criqui MH, et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care. 2002;25:113–120.
[117]
Nwose EU, Richards RS, Bwititi PT. Cardiovascular Risks in Prediabetes: Preliminary Data on “Vasculopathy Triad”. N Am J Med Sci. 2014;6:328–332.
[118]
Trovati M, Anfossi G. Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells. Diabetologia. 1998;41:609–622.
[119]
Suslova TE, Sitozhevskii AV, Ogurkova ON, et al. Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation. Front Physiol. 2015;5;5:501.
[120]
Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation. 2003;107:1017-1023.
[121]
Vinik AI1, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476-1485.
[122]
Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating Tissue Factor Procoagulant Activity and Thrombin Generation in Patients with Type 2: Diabetes: Effects of Insulin and Glucose. J Clin Endocrinol Metab. 2007;92:4352-4358.
[123]
Dokken BB. The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids. Diabetes Spectrum. 2008;21:160-165.
[124]
Gu K, Cowie CC, Harris ML. Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care. 1998; 21:1138–1145.
[125]
Serebruany VL, McKenzie ME, Meister AF, et al. Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure. Pathophysiol Haemost Thromb. 2002;32:8-15.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186